Introduction
Nausea and vomiting are among the most distressing side effects of chemotherapy, affecting more than 70 % of patients in the absence of an antiemetic [1] . Aprepitant, a neurokinin-1 receptor antagonist (NK1-RA), is effective at helping to prevent both acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC), when administered with a serotonin receptor antagonist (5HT3-RA) and dexamethasone [2] [3] [4] [5] . Based on this efficacy, aprepitant is recommended in national guidelines for patients receiving HEC and MEC [6] and it has been a part of Mayo Clinic Rochester practice guidelines for several years.
Fosaprepitant dimeglumine, a phosphorylated analog of aprepitant, is rapidly converted to aprepitant after intravenous (IV) administration. A large randomized control trial concluded that a one-time IV infusion of fosaprepitant was noninferior to a 3-day regimen of oral aprepitant, when combined with dexamethasone and ondansetron [7] . Based on these results and patient convenience, IV fosaprepitant became the recommended version of this drug at Mayo Clinic Rochester, as of January 1, 2011.
Upon making this change, from oral aprepitant to IV fosaprepitant, Mayo Clinic chemotherapy nurses noted that infusion site adverse events were a prominent and substantial problem for a significant number of patients. These nurses reported multiple cases of infusion site erythema and pain either during or shortly after chemotherapy infusions. It was noted that patients receiving doxorubicin/cyclophosphamide (AC) seemed to have an increased incidence of venous toxicity compared to those receiving alternative chemotherapy regimens. Additionally, they noted an increased rate of potential doxorubicin-induced extravasations with fosaprepitant, noting seven extravasations within a 6-month time frame, six of which were associated with doxorubicin while one was associated with epirubicin, compared to 11 extravasations over the course of the preceding 2 years (2008 to 2010). As a result of these findings, Mayo Clinic Rochester guidelines were changed, on November 21, 2011, with recommendations for oral aprepitant to be administered with AC, rather than fosaprepitant.
A review of the comparative trial discussed above [7] revealed that infusion site adverse events such as pain, erythema, induration, and thrombophlebitis were noted to be infrequent, but were observed more frequently with fosaprepitant, compared to aprepitant (2.7 % vs. 0.3 %, respectively). A previous tolerability study, however, had reported that approximately 10 % of fosaprepitant-receiving patients experienced infusion site pain with fosaprepitant [8] while Merck & Co, Inc. reported the incidence of infusion site reactions (including erythema, pruritus, pain, induration, and thrombophlebitis) in 3 % of patients [9] . When the current study was initiated, there was no available information that suggested that this problem was more prominent in men versus women or in patients receiving AC chemotherapy versus other chemotherapeutic agents.
Pursuant to the above, a retrospective study was developed to investigate the incidence of venous toxicity related to fosaprepitant administration at Mayo Clinic Rochester.
Materials and methods
Following Mayo Clinic Institutional Review Board approval of this study, pharmacy records were searched to identify all patients who were initiated on AC chemotherapy who also received either aprepitant or fosaprepitant, from January 2011 to April 2012. Electronic medical record (EMR) data were reviewed on all identified patients. Data collected from the EMR included outpatient and inpatient records. Collected variables included date of birth, gender, ethnicity, primary cancer diagnosis, presence or absence of metastatic disease, chemotherapy regimen, date of chemotherapy, prior history of chemotherapy, current use of corticosteroids, prior use of aprepitant or fosaprepitant, initial antiemetic regimen administered, presence or absence of changes to the antiemetic regimen over the course of chemotherapy, history of prior infusion site adverse events, documentation of an infusion site adverse event, and type of IV access (peripheral vs. central).
Fosaprepitant was prepared and administered per recommended manufacturer guidelines as detailed within the package insert. One hundred and fifty milligrams of fosaprepitant was administered intravenously over 20 to 30 min at a concentration of 1 mg/ml.
Infusion site adverse event details included erythema, induration, pain, swelling, thrombophlebitis, pruritus, vein discoloration, extravasation, or other local reactions at the injection site. Use of fosaprepitant and/or aprepitant was collected for each dose of chemotherapy, including whether patients switched from one to the other.
Statistical analysis
Study data were collected and managed using Research Electronic Data Capture (REDCap) tools [10] . REDCap is a secure, web-based application designed to support data capture for research studies, providing (1) an intuitive interface for validated data entry, (2) audit trails for tracking data manipulation and export procedures, (3) automated export procedures for seamless data downloads to common statistical packages, and (4) procedures for importing data from external sources. Descriptive statistics (mean and standard deviation or N (%)) were summarized overall and by type of IV access and initial antiemetic given.
Results
A total of 148 patients were identified in the pharmacy database and included in this analysis. A detailed description of patient demographics is illustrated in Table 1 . Figure 1 illustrates the use of IV fosaprepitant versus oral aprepitant over time, the first time either was given with AC, demonstrating that IV fosaprepitant was routinely used initially after guidelines were changed, but then oral aprepitant became routinely used following the recognition of an increased incidence of infusion site adverse events. Table 2 portrays the incidence of infusion site adverse events among the patient population, all of which were associated with peripheral venous access, in contrast to no reactions in patients who received therapy through a central venous access device.
Infusion site adverse events associated with fosaprepitant administration were identified in 34 patients, including infusion site pain (n=26), erythema (n=22), swelling (n=12), infusion site hives (n=5), extravasation (n=4), deep venous thrombosis (DVT) (n= 3), superficial thrombosis (n=8), phlebitis/thrombophlebitis (n=5), vein discoloration (n=1), venous engorgement (n=1), venous hardening/induration (n= 4), and local scarring (n=1). Among the 34 patients that experienced an infusion site adverse event, 26 experienced more than one type of event. One patient experienced two separate extravasation events. Of the 98 individual patients who started on IV fosaprepitant, 10 (10 %) changed to oral aprepitant for at least some of the subsequent AC doses. The reasons for the changes were vein toxicity (n=4), notation that other patients were having vein toxicity (n=1), alternative antiemetic management (n=1), and no reasoning was provided (n= 3); additionally, one patient received IV fosaprepitant initially, while awaiting prior authorization, which was changed to oral aprepitant following insurance approval.
Of the patients receiving oral aprepitant, only one had an infusion site adverse event, which was characterized as infusion site erythema following doxorubicin administration. This particular patient had a previous infusion site adverse event at the same site, which was associated with fosaprepitant administration, and, as such, this event may represent a recall reaction, rather than a true adverse event related to aprepitant administration. Of the 44 individual patients who started oral aprepitant, 2 (5 %) changed to IV fosaprepitant for at least some of the subsequent AC doses. One patient changed to IV fosaprepitant to try to get improved nausea management, while no reason was provided by the other patient.
Among the 148 patients included in this analysis, 132 initially had peripheral IV access and 16 had central venous access. Of the 132 patients with peripheral IV access, 10 were transitioned to central venous access. Documented reasons for the change in type of access included infusion site adverse events (n=4), suboptimal venous access (n=2), patient preference (n=1), no documented reason for the change (n=2), and ease of administration (n=1). One patient initially had a peripherally inserted central catheter (PICC), which was transitioned to a peripheral IV for the last two doses of chemotherapy.
Discussion
This record review substantiates the nurses' perception that the incidence of infusion site adverse events associated with fosaprepitant administration was significantly higher than what had been previously reported at the time that the current study was devised. Merck & Co, Inc. [9] described the results of a controlled clinical study to evaluate the safety of patients receiving fosaprepitant (n=1,143) and aprepitant (n=1,169), reporting a 3 % incidence of infusion site reactions in the fosaprepitant group versus 0.5 % in the aprepitant group. Grunberg et al. [7] reported significantly more cases of infusion-associated reactions with fosaprepitant than with aprepitant, but these events were only reported in 2.7 % of those that received fosaprepitant. Additionally, investigator assessment in this trial concluded that only 18 of the 30 reported events in the fosaprepitant group were related to the study medication [7] . Lasseter et al. [8] conducted a study to assess the tolerability of fosaprepitant (either in 100-or 115-mg doses), in comparison to aprepitant, noting an increased incidence of infusion site pain in patients receiving fosaprepitant, 10 % (n=7) for 100 mg and 8 % (n=5) for 115 mg, but no infusion site pain in patients receiving aprepitant. The same investigators noted infusion site erythema in only one patient receiving 100 mg fosaprepitant and infusion site induration in only one patient with the 115-mg dose of fosaprepitant [8] .
The incidence of venous toxicity in the current experience, however, is more comparable to that recently reported by Saito et al. [11] , who conducted a placebo-controlled trial assessing the safety and efficacy of fosaprepitant (n=174) in patients receiving high-dose cisplatin. They found a doubling in the incidence of infusion site adverse events with fosaprepitant (24 %, n= 41), as compared to a placebo (12 %, n=21) (p=0.0068). Among the reported adverse events in their study, 16 % (n=27) experienced pain at the injection site, 5 % (n=9) developed injection site erythema, 3 % (n=6) experienced swelling, 2 % (n=4) developed phlebitis, and 2 % (n=3) had extravasations [11] . Saito et al. noted that only 2-3 % of the infusion reactions were of moderate grade while none of them were severe, without a specific definition of what they considered as moderate or severe reactions.
While the incidences of infusion site reactions are similar in the current study and the Saito et al. study, the current experience supports that the magnitude of this toxicity is more prominent than has been previously reported in any of the other trials. Many patients experienced substantial erythema, swelling, and pain, in addition to concerns regarding doxorubicin extravasations, which can cause clinically significant tissue damage. Granted that the severity of the reactions was not prospectively graded, the nursing records reveal that many of the reactions would have been moderate to severe.
Additionally, a recently presented Japanese abstract provided findings quite similar to the present report. These investigators noted a 12-fold increased risk of venous toxicity in patients who concomitantly received an anthracycline (compared to patients who received an anthracycline without fosaprepitant), but no increase in the risk of venous toxicity in patients who received fosaprepitant along with cisplatin [12] .
It is remarkable to note the difference in the incidence of infusion reactions reported in the Grunberg et al. study [7] (2.7 %) versus the current study. One possible explanation could be related to the relatively high number of Mayo patients who receive AC chemotherapy via a peripheral IV approach, as opposed to a central venous access device, which is used for the majority of patients receiving AC chemotherapy in many practices. Speaking against this explanation, however, is that the Grunberg et al. study was conducted in many countries where implantable IV access devices are not commonly used. Another possible reason for the substantially higher incidence and severity of venous toxicity in the current report may be related to the regimen studied. Doxorubicin is a vesicant, in comparison to cisplatin, which is neither an irritant nor a vesicant. All of the patients in the Grunberg study received cisplatin and they only studied patients for 1 cycle, which likely explains much of the difference. Further work is ongoing to investigate the incidence of fosaprepitant-induced vein toxicity in patients who are receiving non-anthracycline chemotherapy regimens. The current study is one of the few studies to investigate the incidence of fosaprepitant-induced infusion site adverse events. The primary weaknesses of this study are relatively standard limitations associated with retrospective study designs. Data abstracted from clinical records may lead to underascertainment or over-ascertainment of cases of infusion site adverse events due either to under-reporting, over-reporting, or inadequately documenting toxicity data. Lack of blinding to type of antiemetic administered during retrospective review could attribute to bias in determination of infusion site adverse events. Another limitation of this study is that the study population is comprised primarily of middle-aged Caucasian women who live in the United States Midwest and therefore may not be generalizable to other patient populations.
Although fosaprepitant has been shown to be non-inferior to aprepitant, for efficacy, in the management of acute and delayed CINV [7] , drug tolerability is also an important factor in determining an antiemetic regimen for patients. The current study supports that the incidence and severity of infusion site adverse events associated with fosaprepitant administration, in a group of patients receiving AC largely through peripheral venous access, are significantly higher than those reported in the literature. Further data are needed to determine whether certain patient populations, fosaprepitant dosing, or coadministration with particular chemotherapeutic agents increases the likelihood of infusion site adverse events.
